[1] Moran A, Gu D, Zhao D, et al. Future cardiovascular disease in china:Markov model and risk factor scenario projections from the coronary heart disease policy model-china. Circ Cardiovasc Qual Outcomes, 2010; 3, 243-52. doi:  10.1161/CIRCOUTCOMES.109.910711
[2] Force M, Catapano AL, Graham I, et al. 2016 esc/eas guidelines for the management of dyslipidaemias:The task force for the management of dyslipidaemias of the european society of cardiology (esc) and european atherosclerosis society (eas) developed with the special contribution of the european assocciation for cardiovascular prevention & rehabilitation (eacpr). Atherosclerosis, 2016; 253, 281-344. doi:  10.1016/j.atherosclerosis.2016.08.018
[3] Rosenberg K. High ldl-c, non-hdl-c levels associated with higher cvd death risk, even in those at low cvd risk. Am J Nurs, 2018; 118, 67. http://www.onacademic.com/detail/journal_1000041622544999_8f6b.html
[4] Wang K, Shan S, Zheng H, et al. Non-hdl-cholesterol to hdl-cholesterol ratio is a better predictor of new-onset non-alcoholic fatty liver disease than non-hdl-cholesterol:A cohort study. Lipids Health Dis, 2018; 17, 196. doi:  10.1186/s12944-018-0848-8
[5] Yokoyama K, Tani S, Matsuo R, et al. Increased triglyceride/high-density lipoprotein cholesterol ratio may be associated with reduction in the low-density lipoprotein particle size:Assessment of atherosclerotic cardiovascular disease risk. Heart Vessels, 2019; 34, 227-36. doi:  10.1007/s00380-018-1247-9
[6] Song PK, Li H, Man QQ, et al. Trends in determinants of hypercholesterolemia among chinese adults between 2002 and 2012:Results from the national nutrition survey. Nutrients, 2017; 9, 279. doi:  10.3390/nu9030279
[7] Joint committee for the revision of guidelines for the prevention and treatment of dyslipidemia in Chinese adults. Guidelines for the prevention and treatment of dyslipidemia in chinese adults (2016 revision). Chinese Circulation Journal, 2016; 31, 937-53. (In Chinese)
[8] National Bureau of Statistics. Tabulation on the 2010 population census of the people's republic of china. China Statistics Press, Beijing, 2012.
[9] Carroll MD, Lacher DA, Sorlie PD, et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA, 2005; 294, 1773-81. doi:  10.1001/jama.294.14.1773
[10] Ferrieres J, Bongard V, Dallongeville J, et al. Trends in plasma lipids, lipoproteins and dyslipidaemias in french adults, 1996-2007. Arch Cardiovasc Dis, 2009; 102, 293-301. doi:  10.1016/j.acvd.2009.02.002
[11] Cohen JD, Cziraky MJ, Cai Q, et al. 30-year trends in serum lipids among United States adults:results from the National Health and Nutrition Examination Surveys Ⅱ, Ⅲ, and 1999-2006. Am J Cardiol, 2010; 106, 969-75. doi:  10.1016/j.amjcard.2010.05.030
[12] Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980:Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet, 2011; 378, 31-40. doi:  10.1016/S0140-6736(11)60679-X
[13] Carroll MD, Kit BK, Lacher DA, et al. Trends in lipids and lipoproteins in us adults, 1988-2010. Jama, 2012; 308, 1545-54. doi:  10.1001/jama.2012.13260
[14] Okamura T. Dyslipidemia and cardiovascular disease:A series of epidemiologic studies in japanese populations. J Epidemiol, 2010; 20, 259-65. doi:  10.2188/jea.JE20100060
[15] Mercado CI, Gregg E, Gillespie C, et al. Trends in lipid profiles and descriptive characteristics of U. S. adults with and without diabetes and cholesterol-lowering medication use-national health and nutrition examination survey, 2003-2012, United States. PloS One, 2018; 13, e0193756. doi:  10.1371/journal.pone.0193756
[16] Ahmed F, Waslien C, Al-Sumaie M, et al. Trends and risk factors of hypercholesterolemia among Kuwaiti adults:National Nutrition Surveillance Data from 1998 to 2009. Nutrition, 2014; 28, 917-23. http://www.sciencedirect.com/science/article/pii/S0899900712000056
[17] Baghbani-Oskouei A, Tohidi M, Asgari S, et al. Serum Lipids during 20 years in the Tehran Lipid and Glucose Study:Prevalence, trends and impact on non-communicable diseases. Int J Endocrinol Metab, 2018; 16, e84750.
[18] Zaid M, Hasnain S. Plasma lipid abnormalities in Pakistani population:trends, associated factors, and clinical implications. Braz J Med Biol Res. 2018; 51, e7239. https://www.onacademic.com/detail/journal_1000040509475810_cd36.html
[19] Nejat A, Mirbolouk M, Mohebi R, et al. Changes in lipid measures and incident coronary heart disease:Tehran lipid & glucose study. Clin Biochem, 2014; 47, 1239-44. doi:  10.1016/j.clinbiochem.2014.03.004
[20] Zhao WH, Zhang J, Zhai Y, et al. Blood lipid profile and prevalence of dyslipidemia in chinese adults. Biomed Environ Sci, 2007; 20, 329-35. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=bes200704013
[21] Nakamura Y, Okuda N, Turin TC, et al. Fatty acids intakes and serum lipid profiles:NIPPON DATA90 and the national nutrition monitoring. J Epidemiol, 2010; 20, S544-8. doi:  10.2188/jea.JE20090223
[22] Kong C, Nimmo L, Elatrozy T, et al. Smoking is associated with increased hepatic lipase activity, insulin resistance, dyslipidaemia and early atherosclerosis in Type 2 diabetes. Atherosclerosis, 2001; 156, 373-8. doi:  10.1016/S0021-9150(00)00664-X
[23] Wood AM, Kaptoge S, Butterworth AS, et al. Risk thresholds for alcohol consumption:combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. Lancet, 2018; 391, 1513-23. doi:  10.1016/S0140-6736(18)30134-X
[24] Joshi SR, Anjana RM, Deepa M, et al. Prevalence of dyslipidemia in urban and rural India:the ICMR-INDIAB study. PLoS One, 2014; 9, e96808. doi:  10.1371/journal.pone.0096808
[25] Klop B, Elte JW, Cabezas MC. Dyslipidemia in obesity:mechanisms and potential targets. Nutrient, 2013; 5, 1218-40. doi:  10.3390/nu5041218
[26] Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease:A scientific statement from the american heart association. Circulation, 2011; 123, 2292-333. doi:  10.1161/CIR.0b013e3182160726
[27] Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet, 2014; 384, 626-35. doi:  10.1016/S0140-6736(14)61177-6
[28] Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease:evidence and guidance for management. Eur Heart J, 2011; 32, 1345-61. doi:  10.1093/eurheartj/ehr112
[29] Huang Y, Gao L, Xie X, et al. Epidemiology of dyslipidemia in chinese adults:Meta-analysis of prevalence, awareness, treatment, and control. Popul Health Metr, 2014; 12, 28. doi:  10.1186/s12963-014-0028-7
[30] Pan L, Yang Z, Wu Y, et al. The prevalence, awareness, treatment and control of dyslipidemia among adults in china. Atherosclerosis, 2016; 248, 2-9. doi:  10.1016/j.atherosclerosis.2016.02.006
[31] Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment:prospectivemeta-analysis of data from 90, 056 participants in 14 randomised trials ofstatins. Lancet, 2005; 366, 1267-78. doi:  10.1016/S0140-6736(05)67394-1
[32] Nicholls SJ, Brandrup-Wognsen G, Palmer M, et al. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol, 2010; 105, 69-76. doi:  10.1016/j.amjcard.2009.08.651
[33] Kong SH, Koo BK, Moon MK. Efficacy of Moderate Intensity Statins in the Treatment of Dyslipidemia in Korean Patients with Type 2 Diabetes Mellitus. Diabetes Metab J, 2017; 41, 23-30. doi:  10.4093/dmj.2017.41.1.23
[34] Otsuka T, Mizuno K, Shinozaki T, et al. Preventive effect of pravastatin on the development of hypertension in patients with hypercholesterolemia:A post-hoc analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. J Clin Lipidol, 2017; 11, 998-1006. doi:  10.1016/j.jacl.2017.05.015
[35] Ang J, Li LJ, He YC, et al. An exploring study on the pharmacodynamics of rosuvastatin in Chinese hypercholesterolemic patients. Chin J Clin Pharm Ther, 2010; 15, 894-900. http://d.old.wanfangdata.com.cn/Periodical/zglcylxyzlx201008012
[36] Zhao S, Peng D. Efficacy and safety of rosuvastatin versus atorvastatin in high-risk Chinese patients with hypercholesterolemia:a randomized, double-blind, active-controlled study. Curr Med Res Opin, 2018; 34, 227-35. doi:  10.1080/03007995.2017.1371584
[37] Wu LX. Efficacy and safety of rosuvastatin in aged patients with coronary heart disease and hypercholesterolemia. Chin Mod Med, 2013; 20, 70-1. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhongguoyy201107003
[38] Li JH, Wang LM, Mi SQ, et al. Awareness rate, treatment rate and control rate of dyslipidemia in chinese adults, 2010. Chin J Prev Med, 2012; 46, 687-91. (In Chinese) http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhyfyx201208004
[39] Song P, Zha M, Yang X, et al. Socioeconomic and geographic variations in the prevalence, awareness, treatment and control of dyslipidemia in middle-aged and older chinese. Atherosclerosis, 2019; 282, 57-66. (In Chinese) doi:  10.1016/j.atherosclerosis.2019.01.005
[40] Zhang FL, Xing YQ, Wu YH, et al. The prevalence, awareness, treatment, and control of dyslipidemia in northeast china:A population-based cross-sectional survey. Lipids Health Dis, 2017; 16, 61. doi:  10.1186/s12944-017-0453-2